NCT06828588View on ClinicalTrials.gov

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions
Locally Advanced CancerMetastatic CancerHER2HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell CarcinomaHER 2 Low-expressing Breast Cancer
Interventions
DRUG

ABY-025 Loading Dose

Subjects will receive a loading dose (400 micrograms) of ABY-025 prior to the \[68Ga\]Ga-ABY-025 infusion.

DRUG

[68Ga]Ga-ABY-025

Subjects receive a tracer dose of \[68Ga\]Ga-ABY-025 and will receive a PET/CT scan a few hours after the injection.

Trial Locations (1)

37232

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
lead

Vanderbilt-Ingram Cancer Center

OTHER